What is the difference between Palmitoylethanolamide and Ultramicronized Palmitoylethanolamide?

Nov 16, 2026

If you work with Palmitoylethanolamide (PEA), you have likely noticed that this ingredient is no longer available in just one form. On the market today, you will encounter standard palmitoylethanolamide and Ultramicronized Palmitoylethanolamide. Each represents a distinct processing approach, and each carries a different level of scientific evidence.

This article aims to clarify the differences objectively, without favoring one form over another, so that formulators and brand owners can make the appropriate decisions based on what the published research actually shows.

 

Standard PEA: starting point

 

Standard PEA is the unprocessed form of the molecule. A 2024 narrative review in Pharmacology & Therapeutics describes naïve PEA as a "large particle size lipid molecule with low solubility and bioavailability." This is not a marketing claim-it is a physicochemical limitation that has driven the development of alternative formulations.

For general wellness products where cost efficiency is the primary constraint, standard PEA remains a reasonable option, particularly when a higher total dose is used to partially compensate for lower absorption. This approach is based on pharmacokinetic principles rather than head-to-head clinical comparisons, which, as noted in a 2016 review, are currently lacking. However, formulators should be aware that the clinical research on PEA has largely shifted toward evaluating ultramicronized formulations, in large part because the bioavailability of naïve PEA is recognized as suboptimal.

 

Ultramicronized PEA: microencapsulation as a delivery approach

 

Ultramicronized PEA is produced through a microencapsulation-based delivery approach. Rather than relying on particle size reduction alone, this technology encapsulates PEA within a wall material-lipid, polymer, or hybrid systems-to protect the active ingredient, modify its release profile, and improve processing characteristics.

The research landscape for microencapsulated PEA is predominantly preclinical and formulation-focused. A 2022 study in Pharmaceutics encapsulated PEA in solid lipid nanoparticles (SLN) with a particle size of approximately 250 nm and encapsulation efficiency of 90%, demonstrating improved PEA dissolution and efficient cellular internalization in C2C12 muscle cell models. This was an in vitro study and did not assess clinical endpoints. A 2025 study in Pharmaceutics produced PEA-loaded hybrid PLGA-lipid nanoparticles at approximately 150 nm with 79% encapsulation efficiency, reporting improved solubility and efficient cellular uptake in C2C12 myoblasts-again a preclinical in vitro investigation. A 2024 study in Pharmaceutics developed PEA-loaded elastic nano-liposomes (PEA-ENL) with particles predominantly in the 50-100 nm range, demonstrating efficient transdermal delivery and enhanced skin retention compared to free PEA, negligible cytotoxicity toward HaCaT cells, and no skin irritation in a human patch test (n=32). This represents a distinct application direction for microencapsulation technology-topical and transdermal delivery-where the encapsulation approach addresses the stratum corneum barrier rather than gastrointestinal absorption.

 

How to choose

 

The choice between standard PEA and ultramicronized PEA should be driven by the product's intended positioning and the level of evidence required to support its claims.

Question 1: Does your product claim require clinical data?

A: If your marketing depends on communicating pain-relief outcomes supported by clinical research, micron-size PEA formulations (including ultramicronized PEA) are currently the only forms with meta-analytic and clinical trial evidence. The 2024 Nutrients meta-analysis and the 2014 neuropathic pain study provide a defensible evidence base-provided you accurately describe the study designs and their limitations.

Question 2: Does your formulation require enhanced absorption or barrier crossing?

A: If your target application involves nerve-related or central nervous system–adjacent positioning, ultramicronized PEA is the form whose particle size is designed to enhance intestinal absorption and which has been shown to cross the blood-brain and blood-spinal cord barriers. The 2024 review's statement on barrier crossing is directly relevant to this positioning, though it should be communicated as a formulation property rather than a clinical guarantee.

Question 3: Does your formulation require protection, controlled release, or a specific delivery format?

A: If your product concept calls for protecting PEA from degradation, modifying its release profile, or incorporating it into a delivery system where particle size reduction alone is insufficient, microencapsulation-based approaches warrant evaluation on formulation grounds. The published research on encapsulated PEA-solid lipid nanoparticles, PLGA-lipid hybrids, and elastic nano-liposomes-demonstrates proof-of-concept for improved dissolution, cellular uptake, and transdermal delivery. However, these are formulation-performance findings, not clinical endpoint data. Claims for this format should therefore be framed around delivery characteristics rather than therapeutic efficacy.

Question 4: When is standard PEA the appropriate choice?

A: When cost efficiency is the primary constraint and your claims do not depend on clinical data. Standard PEA is defensible for high-volume, general-wellness products with appropriately modest claims. It should not be presented as clinically equivalent to ultramicronized PEA.

 

Complementary ingredients from our portfolio

 

Beyond PEA, a finished product often benefits from additional well-characterized ingredients that support a broader market positioning. Our portfolio includes Pine Bark Extract 95% OPC, Pterostilbene Powder, Oleanolic Acid Powder, and Hesperidin 90% Powder. These ingredients are available for formulators seeking to diversify their product concepts, and each carries its own established documentation and specification sheet. We are happy to discuss sourcing, specifications, and sample availability for any of these materials alongside our PEA range. Please note that any formulation or claim decisions remain the responsibility of the brand owner, and we recommend reviewing each ingredient's individual regulatory and evidence status for your target market.

51-Pine Bark Extract 95 OPC

Pine Bark Extract 95% OPC

90-Hesperidin 90 Powder

Hesperidin 90% Powder

Safety: a consistent finding across formulations

 

Across the clinical research, PEA-including ultramicronized forms-has been consistently described as well tolerated. The 2024 Pharmacology & Therapeutics review states that "several preclinical and clinical studies have shown the efficacy, safety and tolerability of ultramicronized PEA." The 2014 neuropathic pain study likewise reported no safety concerns during the treatment period. These findings support a favorable tolerability profile for ultramicronized PEA specifically; whether this profile is identical across all PEA formulations has not been directly compared in head-to-head studies.

 

conclusion

 

Standard PEA and ultramicronized PEA each remain viable formulation options. The responsible approach is to match the formulation to the evidence: if your product's claim depends on clinical pain outcomes, ultramicronized PEA is the form with the strongest published support. If cost is the dominant constraint, standard PEA remains an option with a well-documented safety profile, provided your claims are appropriately modest.

At Inhealth Nature, we supply both standard PEA and ultramicronized PEA. Whether you are developing a general wellness blend or a targeted support product, our team can help you navigate the options and select the ingredient that matches your formulation and evidence requirements.

For collaboration inquiries, formulation support, or product samples, please contact us at info@inhealthnature.com. We look forward to working with you.

 

References

[1] Nobili S, Micheli L, Lucarini E, et al. Ultramicronized N-palmitoylethanolamine associated with analgesics: Effects against persistent pain. Pharmacol Ther. 2024;258:108649. doi:10.1016/j.pharmthera.2024.108649. PMID: 38615798.

[2] Schweiger V, Schievano C, Martini A, et al. Extended Treatment with Micron-Size Oral Palmitoylethanolamide (PEA) in Chronic Pain: A Systematic Review and Meta-Analysis. Nutrients. 2024;16(11):1653. doi:10.3390/nu16111653. PMID: 38892586.

[3] Cocito D, Peci E, Ciaramitaro P, et al. Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain. Pain Res Treat. 2014;2014:854560. doi:10.1155/2014/854560. PMID: 24967102.

[4] Kriek R. Palmitoylethanolamide: problems regarding micronization, ultra-micronization and additives. Inflammopharmacology. 2014;22(3):195-198. doi:10.1007/s10787-014-0202-3. PMID: 24647619.

[5] Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. 2016;82(4):932-942. doi:10.1111/bcp.13020. PMID: 27220803.